Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Часто задаваемые вопросы
В каком секторе работает Argent BioPharma Limited (RGTLF)?
Argent BioPharma Limited относится к сектору Прочее.
Какова текущая цена акций Argent BioPharma Limited (RGTLF)?
По последним данным, цена акций Argent BioPharma Limited составляет 0,01 $, предыдущее закрытие — 0,01 $.
Выплачивает ли Argent BioPharma Limited (RGTLF) дивиденды?
Нет, Argent BioPharma Limited не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Argent BioPharma Limited (RGTLF)?
У компании Argent BioPharma Limited бета 0.515, что указывает на более низкую волатильность по сравнению с рынком в целом.
